Clinical research company George Clinical said on Thursday that its health and medical expertise, operational infrastructure and data science teams are actively advising stakeholders on potential COVID-19 vaccine and treatment studies.
With deep roots in the Asia-Pacific (APAC) region and knowing geographic pattern of the COVID-19 pandemic, the company's team has adapted and applied learnings to trials in other locations as the pandemic spread brings uncommon challenges to ongoing clinical trials.
In this extraordinary situation, the company's is working with regulatory bodies and local ethics committees across the USA, UK, Europe and APAC to ensure and speed up the start up trial. The operations and data sciences teams bring expertise to provide unique solutions to new study challenges on COVID-19 solutions in order to expedite trial execution globally.
Through flexibility around the study design and operational implementation, the data can be generated quickly, with highest focus on patient safety and the treatments can be adequately reviewed for evaluation and approval in an expeditious manner, added the company.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma